Clareo Health | The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of Type 1 or Type 2 diabetes and confirmed peripheral neuropathy
Have adequate circulation to the foot
Have an ulcer area at screening up to 6 cm\^2
Up to date on all age-appropriate cancer screenings per local standards
You may not be if
Have current evidence of osteomyelitis, cellulitis, or evidence of systemic infection
Have gangrene present on any part of the affected foot
Known peripheral arterial disease requiring revascularization
Have a glycated hemoglobin A1C level of greater than (\>) 15% assessed at screening
Are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents
Have active malignancy or any history of a malignancy
Use of oral antibiotics at the time of randomization for any reason in participants to be enrolled in Cohorts A, B, E, and any additional uninfected patient cohorts
